Type of Cancer
Phase
Division (Location)
Study ID
NCT#
Brief Description
Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML) (PANTHER)SPONSOR
To find out more about this clinical trial, or to schedule an appointment, call (201) 518-3587.